100 related articles for article (PubMed ID: 18825551)
1. Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents.
Chandra Sekhar KV; Rao VS; Krishna MM
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):871-5. PubMed ID: 18825551
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
Sekhar KV; Rao VS; Devambatla RKV; Kumar MM
Bioorg Med Chem Lett; 2008 Dec; 18(23):6054-7. PubMed ID: 18948000
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and preliminary in vitro and in vivo pharmacological evaluation of 2-{4-[4-(2,5-disubstituted thiazol-4-yl)phenylethyl]piperazin-1-yl}-1,8-naphthyridine-3-carbonitriles as atypical antipsychotic agents.
Gowri Chandra Sekhar KV; Rao VS; Deuther-Conrad W; Reddy AS; Brust P; Krishna Kumar MM
J Enzyme Inhib Med Chem; 2011 Aug; 26(4):561-8. PubMed ID: 21171898
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, computational studies and preliminary pharmacological evaluation of 2-[4-(aryl substituted) piperazin-1-yl] N, N-diphenylacetamides as potential antipsychotics.
Kumar S; Wahi AK; Singh R
Eur J Med Chem; 2011 Sep; 46(9):4753-9. PubMed ID: 21824691
[TBL] [Abstract][Full Text] [Related]
5. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: a novel series of atypical antipsychotic agents.
Park CM; Kim SY; Park WK; Choi JH; Seong CM
Bioorg Med Chem Lett; 2010 Sep; 20(17):5221-4. PubMed ID: 20655748
[TBL] [Abstract][Full Text] [Related]
7. Interactions of N-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-2-aryl-2-yl-acetamides and 1-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-3-aryl-2-yl-ureas with dopamine D2 and 5-hydroxytryptamine 5HT(1A) receptors.
Sukalovic V; Ignjatovic D; Tovilovic G; Andric D; Shakib K; Kostic-Rajacic S; Soskic V
Bioorg Med Chem Lett; 2012 Jun; 22(12):3967-72. PubMed ID: 22607670
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
Zajdel P; Marciniec K; Maślankiewicz A; Grychowska K; Satała G; Duszyńska B; Lenda T; Siwek A; Nowak G; Partyka A; Wróbel D; Jastrzębska-Więsek M; Bojarski AJ; Wesołowska A; Pawłowski M
Eur J Med Chem; 2013 Feb; 60():42-50. PubMed ID: 23279866
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, pharmacological evaluation and descriptor based similarities study of N,N-diphenyl-2-[4-(substituted phenyl)piperazin-1-yl]acetamides as potential antipsychotics.
Dash RC; Bhosale SH; Shelke SM; Suryawanshi MR; Mahadik KR
Med Chem; 2012 Nov; 8(6):1069-75. PubMed ID: 22779792
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential.
Tomić M; Kundaković M; Butorović B; Janać B; Andrić D; Roglić G; Ignjatović D; Kostić-Rajacić S
Bioorg Med Chem Lett; 2004 Aug; 14(16):4263-6. PubMed ID: 15261283
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of halogenated and non-halogenated arylpiperazin-1-yl-ethyl-benzimidazoles as D(2) and 5-HT(2A) receptor ligands.
Tomić M; Vasković D; Tovilović G; Andrić D; Penjišević J; Kostić-Rajačić S
Arch Pharm (Weinheim); 2011 May; 344(5):287-91. PubMed ID: 21509803
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
Norman MH; Rigdon GC; Hall WR; Navas F
J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
[TBL] [Abstract][Full Text] [Related]
14. Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.
Zajdel P; Marciniec K; Maślankiewicz A; Satała G; Duszyńska B; Bojarski AJ; Partyka A; Jastrzębska-Więsek M; Wróbel D; Wesołowska A; Pawłowski M
Bioorg Med Chem; 2012 Feb; 20(4):1545-56. PubMed ID: 22277589
[TBL] [Abstract][Full Text] [Related]
15. 3-substituted-1,2-benzisoxazoles: novel antipsychotic agents.
Davis L; Effland RC; Klein JT; Dunn RW; Geyer HM; Petko WW
Drug Des Discov; 1992 Feb; 8(3):225-40. PubMed ID: 1356026
[TBL] [Abstract][Full Text] [Related]
16. Two new phenylpiperazines with atypical antipsychotic potential.
Tomić M; Ignjatović D; Tovilović G; Andrić D; Roglić G; Kostić-Rajacić S
Bioorg Med Chem Lett; 2007 Nov; 17(21):5749-53. PubMed ID: 17870534
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
18. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Rasmussen K; Benvenga MJ; Bymaster FP; Calligaro DO; Cohen IR; Falcone JF; Hemrick-Luecke SK; Martin FM; Moore NA; Nisenbaum LK; Schaus JM; Sundquist SJ; Tupper DE; Wiernicki TR; Nelson DL
J Pharmacol Exp Ther; 2005 Dec; 315(3):1265-77. PubMed ID: 16141369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
